Jounce sags after ICOS mAb readout

Jounce Therapeutics Inc. (NASDAQ:JNCE) lost $6.22 (35%) to $11.45 Thursday after reporting data from the Phase I/II ICONIC trial evaluating the company's inducible T cell co-stimulator (ICOS) agonist mAb JTX-2011 to treat advanced solid tumors. The data were released late Wednesday in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

JTX-2011 as monotherapy led to one partial response (PR) in seven evaluable gastric cancer patients, for an overall response rate (ORR) of 14%. The therapy led to two cases of stable disease in five evaluable patients with triple-negative breast cancer (TNBC)...